Alamar Biosciences

ALMR

Market cap $1.79B

FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the second quarter 2026 after market close on Monday, August 10, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. | Resulting dataset will be publicly accessible, linked through National Alzheimer's Coordinating Center IDs and open to AI-driven discovery through a national data challenge. | Project is part of the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) portfolio, leveraging academic, philanthropic, and data-sharing partnerships for large-scale biomarker discovery. National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. | Resulting dataset will be publicly accessible, linked through National Alzheimer's Coordinating Center IDs and open to AI-driven discovery through a national data challenge. | Project is part of the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) portfolio, leveraging academic, philanthropic, and data-sharing partnerships for large-scale biomarker discovery.

Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer's disease detection and staging Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer's disease detection and staging

eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer's disease | Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program | Data to be featured in Alamar's workshop at AAIC 2026 eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer's disease | Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program | Data to be featured in Alamar's workshop at AAIC 2026

Cathie Wood added to her positions in SpaceX, Roblox, and Alamar Biosciences on Monday. SpaceX has had its ups and downs, and it's now just 3% higher than its first trade as a public company six trading days ago.

NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices | Workflow extends NULISA into longitudinal, decentralized, and population-scale research NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices | Workflow extends NULISA into longitudinal, decentralized, and population-scale research

FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026.

FREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will be participating in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, Nevada.

FREMONT, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will publish its first quarter 2026 financial results before market open on Friday, May 8, 2026.

FREMONT, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (“Alamar”), a leader in Precision Proteomics dedicated to advancing the early detection of disease, today announced the closing of its upsized initial public offering of 12,937,500 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase an additional 1,687,500 shares of common stock, at a public offering price of $17.00 per share, less underwriting discounts and commissions. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Alamar, were approximately $219.9 million. The shares began trading on the Nasdaq Global Select Market on April 17, 2026 under the ticker symbol “ALMR.”